Abstract
Adjuvant radiation therapy (RT) following breast-conserving surgery (BCS) represents a standard approach for most patients treated with breast-conserving therapy (BCT) for early-stage breast cancer. The first-generation of adjuvant RT schedules delivered daily treatment to the whole breast over 5–7 weeks. Although efficacious, this presented patients with a protracted course of treatment, reducing compliance and quality of life. While hypofractionated whole-breast irradiation (WBI) has become the standard, and part of the second-generation of RT regimens, it still requires 3–4 weeks. Concurrently, partial-breast irradiation (PBI) has also been explored as a technique to complete RT in a much shorter time period (1–3 weeks). There are now seven trials confirming the efficacy of this shorter treatment approach compared with standard WBI. In an effort to further reduce treatment duration, ultra-short WBI and PBI regimens have recently emerged as the third-generation of breast radiation schedules, allowing for the completion of treatment in 5 days or less. With respect to WBI, recent data from the FAST-Forward trial (which evaluated five fractions of WBI delivered in 1 week) demonstrated no difference in clinical outcomes at 5 years, with limited difference in toxicity, compared with hypofractionated 3-week WBI. Regarding PBI, published data on five-fraction regimens delivered in 2 weeks have also demonstrated comparable outcomes at 10 years, with reduced toxicities with long-term follow-up. This report will review additional ongoing studies evaluating even shorter courses of adjuvant RT treatment (one to five fractions), including single-fraction PBI or WBI.
Similar content being viewed by others
References
Smith BD, Bellon JR, Blitzblau R, et al. Radiation therapy for the whole breast: executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Pract Radiat Oncol. 2018;8:145–52.
Early Breast Cancer Trialists’ Collaborative Group (EBCTG). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378:1707–16.
Whelan TJ, Pignol JP, Levine MN, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010;362:513–20.
Haviland JS, Owen JR, Dewar JA, et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of earl breast cancer: 10-year follow-up results of two randomized controlled trials. Lancet Oncol. 2013;14:1086–94.
Brunt AM, Haviland J, Sydenham M, et al. FAST Phase III RCT of radiotherapy hypofractionation for treatment of early breast cancer: 10-year results (CRUKE/04/015). Int J Radiat Oncol Biol Phys. 2018;102:LBA2.
Brunt AM, Haviland JS, Wheatley DA, et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicenter, non-inferiority, randomised, phase 3 trial. Lancet. 2020;395:1613–26.
Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347:1233–41.
Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347:1227–32.
Van Dongen JA, Voogd AC, Fentiman IS, et al. Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J Natl Cancer Inst. 2000;92:1143–50.
Correa C, Hariss EE, Leonardi MC, et al. Accelerated partial breast irradiation: executive summary for the update of an ASTRO evidence-based consensus statement. Pract Radiat Oncol. 2017;17:73–9.
Shah C, Vicini F, Shaitelman SF, et al. The American Brachytherapy Society consensus statement for accelerated partial breast irradiation. Brachytherapy. 2018;17:154–70.
Fentiman IS, Poole C, Tong D, et al. Inadequacy of iridium implant as sole radiation treatment for operable breast cancer. Eur J Cancer. 1996;32A:608–11.
Polgar C, Fodor J, Major T, et al. Breast-conserving therapy with partial or whole breast irradiation: 10-year results of the Budapest randomized trial. Radiother Oncol. 2013;108:197–202.
Shah C, Antonucci JV, Wilkinson JB, et al. Twelve-year clinical outcomes and patterns of failure with accelerated partial breast irradiation versus whole-breast irradiation: results of a matched-pair analysis. Radiother Oncol. 2011;100:210–4.
Kamrava M, Kuske RR, Anderson B, et al. Outcomes of breast cancer patients treated with accelerated partial breast irradiation via multicatheter interstitial brachytherapy: the pooled interstitial sites (PROMIS) experience. Ann Surg Oncol. 2015;22:s404–11.
Strnad V, Ott OJ, Hildebrandt G, et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet. 2016;387:229–38.
Polgar C, Ott OJ, Hildebrandt G, et al. Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2017;18:259–68.
Vicini FA, Cecchini RS, White JR, et al. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet. 2019;394:2155–64.
Shah C, Badiyan S, Ben Wilkinson J, et al. Treatment efficacy with accelerated partial breast irradiation (APBI): final analysis of the American Society of Breast Surgeons MammoSite breast brachytherapy trial. Ann Surg Oncol. 2010;20:3279–85.
Shah C, Khwaja S, Badiyan S, et al. Brachytherapy-based partial breast irradiation is associated with low rates of complications and excellent cosmesis. Brachytherapy. 2013;12:278–84.
Wilkinson JB, Chen PY, Wallace MF, et al. Six-year results from a Phase I/II trial for hypofractionated accelerated partial breast irradiation using a 2-day dose schedule. Am J Clin Oncol. 2018;41:986–91.
Khan AJ, Vicini FA, Brown S, et al. Dosimetric feasibility and acute toxicity in a prospective trial of ultrashort-course accelerated partial breast irradiation (APBI) using a multi-lumen balloon brachytherapy device. Ann Surg Oncol. 2013;20:1295–301.
Khan AJ, Chen PY, Yashar C, et al. Three-fraction accelerated partial breast irradiation (APBI) delivered with brachytherapy applicators is feasible and safe: first results from the TRIUMPH-T trial. Int J Radiat Oncol Biol Phys. 2019;104:67–74.
Hepel JT, Yashar C, Leonard KL, et al. Five fraction accelerated partial breast irradiation using noninvasive image-guided breast brachytherapy: feasibility and acute toxicity. Brachytherapy. 2018;17:825–30.
Showalter SL, Petroni G, Trifletti DM, et al. A novel form of breast intraoperative radiation therapy with CT-guided high-dose rate brachytherapy: results of a prospective Phase I clinical trial. Int J Radiat Oncol Biol Phys. 2016;96:46–54.
Hannoun-Levi JM, Kee DLC, Gal J, et al. Accelerated partial breast irradiation in the elderly: 5-year results of the single fraction elderly breast irradiation (SiFEBI) Phase I/II trial. Brachytherapy. 2020;19:90–6.
Kinj R, Chand ME, Gal J, et al. Five-year oncological outcome after a single fraction of accelerated partial breast irradiation in the elderly. Radiat Oncol. 2019;14:234.
Pignol JP, Caudrelier JM, Crook J, et al. Report on the clinical outcomes of permanent breast seed implant for early-stage breast cancers. Int J Radiat Oncol Biol Phys. 2015;93:614–21.
Livi L, Meattini I, Marrazzo L, et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole-breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial. Eur J Cancer. 2015;51:451–63.
Meattini I, Saieva C, Lucidi S, et al. Accelerated partial breast or whole breast irradiation after breast conservation surgery for patients with early breast cancer: 10-year follow up results of the APBI IMRT Florence randomized phase 3 trial. Cancer Res. 2020;80:GS4-06.
Grendarova P, Roumeliotis M, Quirk S, et al. One-year cosmesis and fibrosis from ACCEL: accelerated partial breast irradiation (APBI) using 27 Gy in 5 fractions. Pract Radiat Oncol. 2019;9(5):e457–64.
Kennedy WR, Thomas MA, Stanley JA, et al. Single-institution Phase ½ prospective clinical trial of single-fraction, high-gradient adjuvant partial-breast irradiation for hormone sensitive Stage -I breast cancer. Int J Radiat Oncol Biol Phys. 2020;107:344–52.
Rahimi A, Thomas K, Spangler A, et al. Preliminary results of a Phase I dose escalation trial for early-stage breast cancer using 5-fraction stereotactic body radiation therapy for partial-breast irradiation. Int J Radiat Oncol Biol Phys. 2017;98:196–205.
Yu CX, Shao X, Zhang J, et al. GammaPod—a new device dedicated for stereotactic radiotherapy of breast cancer. Med Phys. 2013;40(5):051703.
Lozza L, Fariselli L, Sandri M, et al. Partial breast irradiation with CyberKnife after breast conserving surgery: a pilot study in early breast cancer. Radiat Oncol. 2018;13:49.
Horton JK, Blitzblau RC, Yoo S, et al. Preoperative single-fraction partial breast radiation therapy. A novel Phase 1, dose-escalation protocol with radiation response biomarkers. Int J Radiat Oncol Biol Phys. 2015;92:846–55.
Charaghvandi RK, van Asselen B, Philippens ME, et al. Treatment constraints for a single dose external beam preoperative partial breast irradiation in early-stage breast cancer. BMC Cancer. 2017;17:181.
Khan AJ, Arthur DW, Vicini FA. On the road to intraoperative: more ‘proceed with caution’ sign. Oncology. 2013;27:113–4.
Shah C, Wobb J, Khan A. Intraoperative radiation therapy in breast cancer: still not ready for prime time. Ann Surg Oncol. 2016;23:1796–8.
Vaidya JS, Bulsara M, Baum M, et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT: a randomised clinical trial. BMJ. 2020;370:m2836.
Vaidya JS, Bulsara M, Saunders C, et al. Effect of delayed targeted intraoperative radiotherapy versus whole-breast radiotherapy on local control recurrence and survival: long-term results from the TARGIT: a randomized clinical trial in early breast cancer. JAMA Oncol 2020;6:e200249.
Veronesi U, Orecchia R, Maisonneuve P, et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. Lancet Oncol. 2013;14:1269–77.
Kirby AM, MacKenzie M, Coles C, Poortmans P, Yarnold J. Re: long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT—a randomised clinical trial. BMJ. 2020;370:m2836.
Bentzen SM, Haviland JS. No apparent effect of 50 kv intra-operative radiation therapy in loco-regional control after lumpectomy for early breast cancer. BMJ. Epub 28 Aug 2020.
Ganz, PA, Cecchini RS, White JR, et al. Patient-reported outcomes (PROs) in NRG oncology/NSABP B-39/RTOG 0413: a randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) in stage 0, I, or II breast cancer. J Clin Oncol. 2019;37:508.
White JR, Winter K, Cecchini RS, et al. Cosmetic outcome from post-lumpectomy whole breast irradiation (WBI) versus partial breast irradiation (PBI) on the NRG Oncology/NSABP B39-RTOG0413 Phase III Clinical Trial. Int J Radiat Oncol Biol Phys. 2019;105:S5.
Meattini I, Saieva C, Miccinesi G, et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: health-related quality of life final analysis from the Florence Phase 3 trial. Eur J Cancer. 2017;76:17–26.
Dvoark T, Coltey D, Waters J, et al. Contribution of radiation therapy to the overall cost of cancer care for clinical stage IA breast cancer patients; Cancer Res. 2018;78:sPD7-04.
Mariotto AB, Yabroff KR, Shao Y, et al. Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst. 2011;103:117–28.
Shah C, Lanni TB, Saini H, et al. Cost-efficacy of accelerated partial-breast irradiation compared with whole breast irradiation. Breast Cancer Res Treat. 2013;138:127–35.
Smith BD, Pan IW, Shih YC, et al. Adoption of intensity-modulated radiation therapy for breast cancer in the United States. J Natl Cancer Inst. 2011;103:798–809.
Shah C, Ward MC, Tendulkar RD, et al. Cost and cost-effectiveness of image guided partial breast irradiation in comparison to hypofractionated whole breast irradiation. Int J Radiat Oncol Biol Phys. 2019;103:397–402.
Ward MC, Vicini F, Al-Hilli Z, et al. Cost-effectiveness analysis of endocrine therapy alone versus partial-breast irradiation alone versus combined treatment for low-risk hormone-positive early-stage breast cancer in women aged 70 years or older. Breast Cancer Res Treat. 2020;182:355–65.
Centers for Medicare and Medicaid Services. Radiation Oncology Model. https://innovation.cms.gov/innovation-models/radiation-oncology-model. Accessed 31 May 2020.
Grobmyer SR, Lightsey JL, Bryant CM, et al. Low-kilovoltage, single-dose intraoperative radiation therapy for breast cancer: results and impact on a multidisciplinary breast cancer program. J Am Coll Surg. 2013;216:617–23.
Alvarado MD, Mohan AJ, Esserman LJ, et al. Cost-effectiveness of intraoperative radiation therapy for early-stage breast cancer. Ann Surg Oncol. 2013;20: 2873–80.
Shah C, Badiyan S, Khwaja S, et al. Evaluating radiotherapy options in breast cancer: does intraoperative radiotherapy represent the most cost-efficacious option? Clin Breast Cancer. 2014;14:141–6.
Buszek SM, Liny HY, Bedrosian I, et al. Lumpectomy plus hormone or radiation thearpy alone for women aged 70 years or older with hormone receptor-positive early stage breast cancer in the modern era: an analysis of the National Cancer Database. Int J Radiat Oncol Biol Phys. 2019;105:795–802.
Ward MC, Vicini F, Chadha M, et al. Radiation therapy without hormone therapy for women age 70 or above with low-risk early breast cancer: a microsimulation. Int J Radiat Oncol Biol Phys. 2019;105:296–306.
Ward MC, Vicini F, Al-Hilli Z, et al. Cost-effectiveness analysis of endocrine therapy alone versus partial-breast irradiation alone versus combined treatment for low-risk hormone-positive early-stage breast cancer in women aged 70 years or older. Breast Cancer Res Treat. 2020;182(2):355–65.
Khan AJ, Rafique R, Zafar W, et al. Nation-scale adoption of shorter breast radiation therapy schedules can increase survival in resource constrained economies: results from a Markov chain analysis. Int J Radiat Oncol Biol Phys. 2017;97:287–95.
Funding
None.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosures
Chirag Shah is a consultant for Impedimed and PreludeDX, and has received grants from Varian Medical Systems, VisionRT, and PreludeDX. Frank Vicini is Chief Medical Officer at Impedimed; Martin Keisch is a consultant for Hologic; and David Wazer is a member of the Medical Advisory Board of Advanced Radiation Therapy, Inc. Atif Khan and Douglas Arthur have no conflicts of interest to declare.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Shah, C., Keisch, M., Khan, A. et al. Ultra-Short Fraction Schedules as Part of De-intensification Strategies for Early-Stage Breast Cancer. Ann Surg Oncol 28, 5005–5014 (2021). https://doi.org/10.1245/s10434-020-09526-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-020-09526-y